Nissan Chemical Industries Limited

Chugai Seiyaku Kabushiki Kaisha

Michiaki Adachi

Yoshiaki Watanabe

Yuichi Hirai

Hiroo Matsumoto

Shojiro Kadono

Haruhiko Sato

Michito Tagawa

Kazuhiko Ohrai

Takuya Shiraishi

Yoshiyuki Suzuki

Yasuyuki Nakajima

Masahiro Sakaitani

Takanori Shimizu

Keishi Hayashi

Masateru Ohta

Takashi Furusato

Yasutaka Takada

Nobuya Ishii

Masanori Nishioka

Masami Hasegawa

Hisayuki Watanabe

Masataka Minami

Koji Toyama

Masami Yasukawa

Noriko Saito

Hiroshi Ohya

Yuji Yoshimura

Syuji Morikiyo

Yusuke Shintani

Mitsugu Futagawa

Hiroshi Nagai

Koichi Yasutake

Jun Egi

Megumi Ueno

Masakazu Sugiyama

Yusuke Inaba

Takeshi Kawazu

Daiki Takahashi

There is provided a novel triazinone compound that has an excellent T-type voltage-dependent calcium channel inhibitory activity and is specifically useful for treatment of pain. A compound of Formula (I), a tautomer of the compound, a pharmaceutically acceptable salt thereof, or a solvate thereof: where each substituent is defined in detail in the description or claims, for example Ris H or Calkoxy, etc., each of Land Lis independently a single bond or NR, etc., Lis Calkylene, etc., A is Caryl or 5 to 10-membered heteroaryl which is optionally substituted, etc., B is Ccycloalkylene, etc., D is Caryl or 5 to 10-membered heteroaryl which is optionally substituted, etc.

Triazinone compound and T-type calcium channel inhibitor

The present invention provides novel &#x3b1;-amino acid derivatives of formula (1): (wherein, R, R, R, R, X and Y are as defined in the claims) or pharmaceutically acceptable salts, prodrugs or solvates thereof. The derivatives of formula (1) have &#x3b2;ARK1 inhibitory activity and are useful for preventing or treating heart failure. Moreover, the derivatives of formula (1) also have antitumor activity, particularly dual inhibitory activity on Aurora kinase and CDK, and are useful for cell proliferative diseases such as cancer.

&#x3b1;-amino acid derivatives and medicaments containing the same as an active ingredient

A method for producing an alkyl (3R,5S)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxy-6-heptenoate of the formula (1) (wherein R is a Calkyl group), which is an intermediate for a cholesterol-reducing agent (a HMG-CoA reductase inhibitor), etc. A solution containing a compound of the formula (1) is subjected to liquid chromatography treatment using silica gel as the packing material, to separate its epimers contained therein. 

Method for producing a 3,5-dihydroxy-6-heptenoate

Cyclooctadiene derivatives

Growing community of inventors

Funabashi, Japan

Michiaki Adachi